American Academy of Neurology

Alliance for Aging Research Criticizes CMS Decision to Restrict Access to Alzheimer's Therapies

Retrieved on: 
Thursday, February 23, 2023
Clinical trial, NCD, Centers for Medicare & Medicaid Services, National coverage determination, Cancer, HHS, Alliance for Aging Research, Rare, ALS, AAN, CED, Research, FDA, Patient, American Academy of Neurology, CMS, Ageing, Medicare, White, Biden administration COVID-19 action plan, White House, American Academy, Health insurance, Pharmaceutical industry, Alzheimer's disease

CMS's decision ignores continuously mounting scientific evidence showing that these monoclonal antibodies are effective at delaying the debilitating and deadly progression of Alzheimer's.

Key Points: 
  • CMS's decision ignores continuously mounting scientific evidence showing that these monoclonal antibodies are effective at delaying the debilitating and deadly progression of Alzheimer's.
  • It abuses an extralegal paradigm called coverage with evidence development (CED) to ration access to these therapies.
  • With this decision, CMS has declared that people with Alzheimer's should have no such expectations.
  • The agency's statement reveals a stunning lack of accountability by CMS Administrator Brooks-LaSure, HHS Secretary Becerra, and the Biden Administration.

Is Living Close to Parks, Water Better for Your Brain?

Retrieved on: 
Wednesday, February 22, 2023
Parkinson's disease, Social media, American Academy of Neurology, Nursing, CQD, Washington State University, Nervous system, AAN, Depression, Cemetery, Anxiety, Migraine, Public, Annual general meeting, River, Risk, Brain, Research, Center for Economic Studies (U.S. Census Bureau), Alzheimer's disease, Hope, Dementia, DSM-IV codes, Korea Disease Control and Prevention Agency, College of Medicine, Epilepsy, Multiple sclerosis, Water, Stroke, Blue space, Concussion, Mental health, Lake, American Academy, Road, Pharmaceutical industry, HMCS Kootenay (DDE 258), Neurology

MINNEAPOLIS, Feb. 22, 2023 /PRNewswire/ -- Living closer to outdoor spaces and water sources may reduce older people's risk of having serious psychological distress, which can lead to mild cognitive impairment and dementia, according to a preliminary study released February 22, 2023, that will be presented at the American Academy of Neurology's 75th Annual Meeting being held in person in Boston and live online from April 22-27, 2023.

Key Points: 
  • "Our hope is that this study showing better mental health among people living close to parks and water will trigger other studies about how these benefits work and whether this proximity can help prevent or delay mild cognitive impairment and dementia."
  • The study involved 42,980 people age 65 or older living in urban areas in the state of Washington.
  • Researchers looked at data from the U.S. Census and the Centers for Disease Control and Prevention to identify how close participants lived to green and blue spaces.
  • Blue space was defined as water bodies such as lakes, reservoirs, large rivers and coasts.

Slow Recovery from Concussion? Exercise, Breathing Practice May Improve Symptoms

Retrieved on: 
Tuesday, February 21, 2023
Brain, Dizziness, Memory, Nervous system, Attention, Sleep, Concussion, DSM-IV codes, American Academy of Neurology, Thought, Annual general meeting, Texas Woman's University, AAN, Body mass index, Depression, University, Autonomic nervous system, Research, Alzheimer's disease, Stroke, Headache, Heart rate, American Academy, Migraine, Recreation, Exercise, Multiple sclerosis, Parkinson's disease, Epilepsy, Texas Woman, Cognition, Social media, Doctor of Philosophy, Pharmaceutical industry, Dietary supplement, Medical imaging, Neurology

Slow recovery was defined as taking more than one month for concussion symptoms to resolve.

Key Points: 
  • Slow recovery was defined as taking more than one month for concussion symptoms to resolve.
  • Symptoms can include headache and dizziness, depression and mood problems as well as problems with memory and concentration.
  • "Our study used a handheld biofeedback device to help people train their breathing to match their heart rate patterns.
  • The biofeedback group practiced breathing at a slow rate with a computer program for 20 minutes a night, four nights a week.

AEON Biopharma to Host Key Opinion Leader Webinar on Past, Present, and Potential Future Treatments for Migraine on February 24th

Retrieved on: 
Tuesday, February 14, 2023
AEON, Dartmouth College, University of Washington School of Medicine, Weill Cornell Medicine, AHS, Publication, Dartmouth–Hitchcock Medical Center, Physician Payments Sunshine Act, Education, American Academy of Neurology, Research, City of London Finance Committee, Headache (journal), Editor-in-chief, Geisel School of Medicine, American Board of Commissioners for Foreign Missions, American Board of Psychiatry and Neurology, American Academy, Migraine, Psychiatry, Government in the Sunshine Act, KOL, Book, Yale College, Pharmaceutical industry, Headache, Neurology, MD

The event will highlight the differences between monotherapy and combination therapy in the context of migraine treatments.

Key Points: 
  • The event will highlight the differences between monotherapy and combination therapy in the context of migraine treatments.
  • Additionally, AEON’s leadership team will provide an update on clinical developments and the predicted timeline of future product development.
  • He is Director of the Dartmouth Headache Center in the Department of Neurology of Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
  • Dr. Tepper was Director of the Scottsdale Headache Symposium CME course of the American Headache Society from 2008 to 2020.

Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Thursday, February 16, 2023
Mental Health, Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Function (mathematics), NDA, PPD, Safety, Priority review, Proceedings of the Institution of Mechanical Engineers, Part B, Neuropsychiatry, Spectrum, Part, Learning, ECNP, D, Social, Memory, Commercialization, Zuranolone, Disorder, Shionogi, Depression, Grammatical mood, American Academy, GABAA, GABA, AD, Rehabilitation, Prescription Drug User Fee Act, HD, R, GABAA receptor positive allosteric modulator, DSM-IV codes, SG, PDUFA, PAM, Tremor, Patient, Incidence, Essential tremor, Webcast, NEST, Therapy, CIV, MDD, Huntington's disease, Epilepsy, Cognition, Woman, PD, MCI, NMDA, American Academy of Neurology, Medical Affairs Bureau, Plasma, Deficit spending, Conference, IND, Pharmaceutical industry, Medical device, Hunting, Design, Beauty salon, Boilermaker, Cryptocurrency, Biogen, Sage

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.
  • In 2022, Sage and Biogen advanced commercialization plans for zuranolone through scientific exchange, permitted interactions with payers and disease state education in MDD and PPD.
  • Net Loss: Net loss was $147.1 million for the fourth quarter of 2022 compared to $124.7 million for the same period in 2021.
  • ET to review its fourth quarter and full year 2022 financial results and discuss recent corporate updates.

Can the Lingering Effects of a Mild Case of COVID-19 Change Your Brain

Retrieved on: 
Monday, February 20, 2023
Grey, Brain, Memory, Nervous system, Concussion, Yasuda, DSM-IV codes, American Academy of Neurology, Annual general meeting, COVID-19, AAN, Depression, University, Research, Alzheimer's disease, Cyclothymia, Anxiety, Stroke, American Academy, Migraine, Paulo, Infection, Multiple sclerosis, Parkinson's disease, COVID, Epilepsy, Quality of life, Social media, State University of Campinas, Doctor of Philosophy, MD, Pig, Pharmaceutical industry, Medical imaging, Neurology

MINNEAPOLIS, Feb. 20, 2023 /PRNewswire/ -- People with long COVID who experience anxiety and depression months after a mild case of COVID-19 may have brain changes that affect the function and structure of the brain, according to a preliminary study released February 20, 2023, that will be presented at the American Academy of Neurology's 75th Annual Meeting being held in person in Boston and live online from April 22-27, 2023.

Key Points: 
  • "Our findings are concerning, as even people with a mild case of COVID-19 are showing changes in their brains months later.
  • More studies are needed to hopefully identify treatments to prevent any long-term effects on people's quality of life."
  • The study involved 254 people with an average age of 41 who had a mild COVID-19 infection an average of three months earlier.
  • Researchers also looked at brain function and changes in connectivity—how the brain communicates—between areas of the brain.

Vial Announces New Central Nervous System Scientific Advisory Board Member, Dr. Jacqueline French of the Epilepsy Study Consortium and NYU Grossman School of Medicine.

Retrieved on: 
Friday, January 13, 2023
NYU Langone Health, SAB, EEG, Mount Sinai Hospital, CNS, International League Against Epilepsy, AAN, MD, Epilepsy, Drug discovery, National Association of Epilepsy Centers, Patient, Yale University, American Academy, American Academy of Neurology, Research, SAN, Brown University, NYU, Fine chemical, Pharmaceutical industry, Vial, Neurology

Dr. French is a professor of neurology at the NYU Grossman School of Medicine, co-director of epilepsy clinical trials for NYU Langone Health's Comprehensive Epilepsy Center, and president, director, and founder of The Epilepsy Study Consortium.

Key Points: 
  • Dr. French is a professor of neurology at the NYU Grossman School of Medicine, co-director of epilepsy clinical trials for NYU Langone Health's Comprehensive Epilepsy Center, and president, director, and founder of The Epilepsy Study Consortium.
  • After receiving her medical education at Brown University, she completed a residency in neurology at Mount Sinai Hospital in New York.
  • Thereafter, she pursued further training through a fellowship in EEG and epilepsy at Mount Sinai Hospital and Yale University.
  • We are pleased to welcome Dr. French as she is an esteemed leader in clinical neurology research," said Simon Burns, CEO and Co-founder of Vial.

Verana Health and Sight Sciences Collaborate on Glaucoma Research Using Curated Real-World Data from the IRIS Registry

Retrieved on: 
Wednesday, January 4, 2023
Exocrine gland, SAN, HCP, Optic nerve, Surgical instrument, Duane syndrome, Safety, Diabetic retinopathy, Health, Research, American Academy, Intraocular pressure, Patient, Trabecular meshwork, American Academy of Ophthalmology, American Academy of Neurology, PARK, IOP, Machine Intelligence Research Institute, Glaucoma, FDA, State, Geographic atrophy, Trauma, MD, Data management, American Urological Association, Severe cognitive impairment, Database, Doctor of Philosophy, RWD, MIGS, Quality of life, Surgeon, Catheter, HCPS, Laika (EHR testing framework), Medicine, Eye, IRIS, OMNI, MGD, Physician, Cataract, Pharmaceutical industry, Dentistry, Medical imaging, Medical device, Ophthalmology

SAN FRANCISCO and MENLO PARK Calif., Jan. 4, 2023 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data (RWD)—and Sight Sciences, Inc. (NASDAQ: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced a research collaboration designed to provide insights that may lead to improved outcomes for patients with primary open-angle glaucoma (POAG).

Key Points: 
  • Powered by real-world glaucoma data curated from the American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight), Qdata Glaucoma is the only data module that captures the full, real-world glaucoma patient journey.
  • This fit-for-purpose data module offers curated data for:
    The IRIS Registry is one of the largest specialty society clinical data registries in all of medicine and the first comprehensive eye disease clinical registry in the U.S.
  • Michael Mbagwu, MD, senior medical director for Verana Health says, "Sight Sciences shares our goal of improving outcomes and treatments for people with glaucoma.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQ® population health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata®.

Verana Health Study of Patients with Dry Age-Related Macular Degeneration Reveals Compelling New Insights Published in International Ophthalmology Journal

Retrieved on: 
Thursday, December 15, 2022
Visual acuity, Physician, EHR, Geographic atrophy, Severe cognitive impairment, HCPS, Data management, HCP, GA, Varnaq, AMD, American Academy, American Academy of Ophthalmology, Macular degeneration, Patient, Vance DeGeneres, American Academy of Neurology, Research, Disease, IRIS, Medicine, Health, Stanford University School of Medicine, Quality of life, Risk, Multimedia, American Urological Association, RWD, SAN, Machine Intelligence Research Institute, Pharmaceutical industry, Publishing, Medical imaging, Therapy, Ophthalmology

SAN FRANCISCO, Dec. 15, 2022 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data—today announced that Ophthalmology and Therapy, an international, peer-reviewed medical journal, has published the results of a study Verana Health conducted to analyze American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight) data for insights into characterizing the most common form of vision loss in the elderly population, age-related macular degeneration (AMD). The study, "Dry Age-Related Macular Degeneration: Distribution of Visual Acuity and Progression Risk in a Large Registry," is a novel study to report on how the stage of disease, as determined by visual acuity (VA), can help predict the risk of progression in dry AMD (dAMD) by stage.

Key Points: 
  • Macular degeneration occurs when a person's retina becomes damaged over time, leading to different levels of vision loss.
  • The study used curated real-world data (RWD) from the Academy IRIS Registrymanaged by Verana Health's VeraQ population health data engineto better understand how patients progress through the stages of dAMD.
  • To request a copy ofthe recently published study, conducted by Dr. Leng and a team of researchers from Verana Health, visit: veranahealth.com/amd-manuscript .
  • Verana Health's quality data and insights help drive progress in medicine to enhance the quality of care and quality of life for patients.

Research links gene variants to medication-induced fatal brain infection

Retrieved on: 
Wednesday, December 14, 2022
Emerald, Frontiers, Standard of care, Boxed warning, American Academy of Neurology, JC, Rheumatoid arthritis, Sclerosis, American Academy, Genetics, Parkinson's disease, Patient, BRCA, Research, JCV, MS, Precision medicine, Alzheimer's disease, Perelman School of Medicine at the University of Pennsylvania, Breast cancer, Pediatrics, FDA, Black box, Lymphatic system, Human polyomavirus 2, PML, University, Natalizumab, Crohn's disease, Brain, Progressive multifocal leukoencephalopathy, Multiple sclerosis, Risk, Vaccine, Health insurance, Dietary supplement, Pharmaceutical industry, Autism, Endometriosis, Neurology, Medicine

NEWPORT BEACH, Calif., Dec. 14, 2022 /PRNewswire/ --New research has confirmed a strong link between four genetic mutations and progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection that can be triggered by dozens of FDA-approved drugs.

Key Points: 
  • NEWPORT BEACH, Calif., Dec. 14, 2022 /PRNewswire/ --New research has confirmed a strong link between four genetic mutations and progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection that can be triggered by dozens of FDA-approved drugs.
  • The research will allow doctors to screen out patients with the highest risk of PML.
  • The research, published in Frontiers in Neurology onDecember 14, will allow doctors to screen out patients with the highest risk of PML.
  • The study found that in people taking PML-inducing drugs, having one of four genetic variants increased the risk of PML 8.7 times on average.